Please ensure Javascript is enabled for purposes of website accessibility

Tandem Diabetes Care Pumps Up Sales Dramatically in Q2

By Keith Speights – Aug 2, 2019 at 7:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The insulin pump maker trounced analysts' top- and bottom-line estimates on strong sales growth.

Tandem Diabetes Care (TNDM -0.61%) enjoyed a solid first quarter with revenue jumping a whopping 142% year over year. And the company's net loss decreased to $23 million from the prior-year period of $32.7 million. 

Investors wondering if Tandem would be able to keep up this momentum in the second quarter had their questions were answered when the company reported its Q2 results after the market closed on Thursday. Here's what you need to know about Tandem's Q2 update.

Tandem insulin pump

Image source: Tandem Diabetes Care.

By the numbers

Tandem announced that its revenue jumped 173% in the second quarter to $93.3 million. This blew away the average analysts' revenue estimate of a little over $70 million.

The company reported a net loss in the second quarter on a generally accepted accounting principles (GAAP) basis of $1.5 million, or $0.03 per share. This was a major improvement from the net loss of $59.4 million, or $1.17 per share, reported in the same quarter of 2018. Analysts were expecting a Q2 net loss of $0.25 per share.

Tandem ended the second quarter with cash, cash equivalents, and short-term investments of $131.4 million. This reflected a $2.4 million increase from the end of 2018.

Behind the numbers

The big story for Tandem in the second quarter was increased worldwide pump shipments. Shipments jumped by 290% year over year to 21,258 pumps. According to CEO John Sheridan, the company's pump shipments in the first half of 2019 were more than the company shipped in all of 2018.

Domestic U.S. sales for pumps increased 106% year over year to $70.4 million. International sales in Q2 totaled $22.9 million. Because international shipment didn't begin until the third quarter of 2018, there was no comparison with the prior-year period.

Tandem's bottom line improved in large part as a result of its higher sales. Its net loss would have been even better but the company incurred a $0.4 million noncash charge for the change in fair value of certain outstanding warrants.

Looking ahead

Tandem now projects sales to be between $350 million and $365 million for full-year 2019. This is an increase from the prior guidance of $300 million to $315 million. One key reason for the improved overall outlook is that Tandem now expects international sales to be between $55 million and $60 million, up from $45 million to $50 million.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Tandem Diabetes Care Stock Quote
Tandem Diabetes Care
$52.20 (-0.61%) $0.32

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.